Bahl & Gaynor Inc. raised its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 0.7% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 128,645 shares of the biopharmaceutical company’s stock after purchasing an additional 950 shares during the quarter. Bahl & Gaynor Inc.’s holdings in Bristol-Myers Squibb were worth $7,518,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Blue Chip Partners Inc. grew its stake in shares of Bristol-Myers Squibb by 0.7% in the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after acquiring an additional 15 shares during the period. Jackson Grant Investment Advisers Inc. grew its stake in shares of Bristol-Myers Squibb by 0.4% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock worth $218,000 after acquiring an additional 15 shares during the period. Keel Point LLC grew its stake in shares of Bristol-Myers Squibb by 0.3% in the first quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock worth $342,000 after acquiring an additional 18 shares during the period. Shayne & CO. LLC grew its stake in shares of Bristol-Myers Squibb by 0.6% in the second quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock worth $225,000 after acquiring an additional 24 shares during the period. Finally, Chilton Investment Co. LLC grew its stake in shares of Bristol-Myers Squibb by 0.5% in the second quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock worth $294,000 after acquiring an additional 26 shares during the period. Institutional investors and hedge funds own 69.82% of the company’s stock.

Bristol-Myers Squibb Company (BMY) opened at $62.47 on Tuesday. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. The stock has a market cap of $103,504.91, a P/E ratio of 21.36, a P/E/G ratio of 2.40 and a beta of 1.18. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The business had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.77 EPS. analysts expect that Bristol-Myers Squibb Company will post 2.99 EPS for the current year.

A number of analysts have recently commented on the stock. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. SunTrust Banks upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Monday, October 30th. Credit Suisse Group reiterated a “hold” rating and issued a $61.00 price target (up from $58.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Piper Jaffray Companies reiterated a “hold” rating and issued a $60.00 price target on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Finally, BMO Capital Markets set a $49.00 price target on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $64.93.

In related news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the transaction, the senior vice president now owns 46,297 shares of the company’s stock, valued at $2,777,820. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.23% of the company’s stock.

WARNING: “Bahl & Gaynor Inc. Has $7.52 Million Holdings in Bristol-Myers Squibb Company (BMY)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/05/bahl-gaynor-inc-has-7-52-million-holdings-in-bristol-myers-squibb-company-bmy.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.